Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

被引:34
|
作者
Horowitz, Mia [1 ]
Braunstein, Hila [1 ]
Zimran, Ari [2 ,3 ]
Revel-Vilk, Shoshana [2 ,3 ]
Goker-Alpan, Ozlem [4 ]
机构
[1] Tel Aviv Univ, Schmunis Sch Biomed & Canc Res, IL-69978 Tel Aviv, Israel
[2] Shaare Zedek Med Ctr, Gaucher Unit, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA
关键词
Gaucher disease; Glucocerebrosidase (GCase); Parkinson disease; Misfolding; Unfolded Protein Response (UPR); UNFOLDED PROTEIN RESPONSE; SPHINGOLIPID ACTIVATOR PROTEINS; HUMAN GLUCOCEREBROSIDASE GENE; ENZYME REPLACEMENT THERAPY; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; BETA-GLUCOSIDASE; GBA MUTATIONS; RECOMBINANT GLUCOCEREBROSIDASE; SUBSTANTIA-NIGRA;
D O I
10.1016/j.addr.2022.114402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-beta-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is a-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in similar to 5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes a-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of a-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Molecular Mechanisms Underlying Alzheimer’s and Parkinson’s Disease and the Possibility of Their Neutralization
    Nevzglyadova O.V.
    Mikhailova E.V.
    Soidla T.R.
    Cell and Tissue Biology, 2023, 17 (6) : 593 - 607
  • [22] Molecular mechanisms underlying familial parkinson's disease - Towards neuroprotective therapy
    Takahashi, Ryosuke
    NEUROSCIENCE RESEARCH, 2009, 65 : S29 - S29
  • [23] CELLULAR AND MOLECULAR MECHANISMS OF DISEASE
    MOSSMAN, BT
    REVIEWS IN MINERALOGY, 1993, 28 : 513 - 521
  • [24] An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer's Disease
    Ratan, Yashumati
    Rajput, Aishwarya
    Maleysm, Sushmita
    Pareek, Aaushi
    Jain, Vivek
    Pareek, Ashutosh
    Kaur, Ranjeet
    Singh, Gurjit
    BIOMEDICINES, 2023, 11 (05)
  • [25] PRINCIPLES OF CELLULAR-MOLECULAR MECHANISMS UNDERLYING NEURON FUNCTIONS
    Ratushnyak, Alexander S.
    Zapara, Tatiana A.
    JOURNAL OF INTEGRATIVE NEUROSCIENCE, 2009, 8 (04) : 453 - 469
  • [26] Cellular mechanisms underlying β-amyloid generation and its implications for Alzheimer's disease
    Rajendran, L.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 66 - 66
  • [27] Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease
    Gronbaek-Thygesen, Martin
    Hartmann-Petersen, Rasmus
    CELL AND BIOSCIENCE, 2024, 14 (01):
  • [28] Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease
    Martin Grønbæk-Thygesen
    Rasmus Hartmann-Petersen
    Cell & Bioscience, 14
  • [29] Parkinson disease: from pathology to molecular disease mechanisms
    Dexter, David T.
    Jenner, Peter
    FREE RADICAL BIOLOGY AND MEDICINE, 2013, 62 : 132 - 144
  • [30] Cellular and Synaptic Dysfunctions in Parkinson's Disease: Stepping Out of the Striatum
    Mallet, Nicolas
    Delgado, Lorena
    Chazalon, Marine
    Miguelez, Cristina
    Baufreton, Jerome
    CELLS, 2019, 8 (09)